TACE联合放疗对原发性肝癌合并门静脉癌栓患者生存的影响

  目的  观察TACE联合放疗对原发性肝癌合并门静脉癌栓患者生存的影响。   方法  收集福建省肿瘤医院2005年1月至2010年1月间收治的原发性肝癌合并门静脉癌栓患者52例，分为观察组和对照组:观察组32例，采用肝动脉化疗栓塞联合三维适形放射治疗；对照组20例，单纯采用肝动脉化疗栓塞治疗。观察两组患者的疗效及患者的生存时间和1年生存率，对患者生存质量进行评分。   结果  观察组患者总有效率78.1%，显著优于对照组（45.0%）；观察组患者总生存时间和1年生存率均显著优于对照组；两组不良反应的发生率无显著性差异；治疗后生存质量评分观察组低于对照组，但治疗后3个月生存质量评分观察组显著优于对照组。   结论  TACE联合放疗可显著提高患者的疗效，延长生存时间，提高1年生存率，改善患者生存质量。 

Effects of Transcatheter Hepatic Arterial Chemoembolization Combined with Radiotherapy on the Survival of Primary Hepatic Carcinoma Patients with Portal Vein Tumor Thrombus

  Objective  To observe the effects of transcatheter hepatic arterial chemoembolization combined with radiotherapy on the survival of primary hepatic carcinoma patients with portal vein tumor thrombus.   Methods  The medical data of 52 primary hepatic carcinoma patients with portal vein tumor thrombus admitted to Fujian Cancer Hospital between January 2005 and January 2010 were collected. The patients were divided into observation and control groups. The 32 patients in the observation group received transcatheter hepatic arterial chemoembolization combined with three-dimensional conformal radiotherapy. The 20 patients in the control group received transcatheter hepatic arterial chemoembolization only. The curative effects, survival time, 1-year survival rates, and survival quality scores were observed.   Results  The total effective rate of the observation group was 78.1%, which was significantly higher than that of the control group (45.0%). Moreover, the 1-year survival rate of the observation group was significantly higher than that of the control group. No significant differences in adverse effects were observed between the two groups. After therapy, the survival quality score of the observation group was lower than that of the control group, but it became significantly higher than that of the control group after 3 months.   Conclusion  Transcatheter hepatic arterial chemoembolization combined with radiotherapy could improve the curative effect, prolong the survival time, improve the 1-year survival rate, and improve the survival quality score of primary hepatic carcinoma patients with portal vein tumor thrombus.